Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332579 · ClinicalTrials.gov registry record · Phase 2
Double-Blind Naltrexone in Kleptomania
A Phase 2 study of Kleptomania, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00332579: Completed Phase 2 study of Kleptomania, sponsored by University of Minnesota.
NCT00332579 is a Phase 2 study of Kleptomania that has completed, run by University of Minnesota. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00332579, a Phase 2 study of Kleptomania, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the proposed study is to evaluate the efficacy and safety of naltrexone in kleptomania.
Primary Outcome
The K-YBOCS measures symptom severity (urges/thoughts and behavior) across the past week. Scores range from 0 (no symptoms) to 40 (highest symptom severity).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Naltrexone
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-05-01 |
| Est. Completion | 2008-09-01 |
| Phase | Phase 2 |
What the finished NCT00332579 record still lists
NCT00332579 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Kleptomania appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00332579 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00332579 about?
NCT00332579 is a clinical study titled "Double-Blind Naltrexone in Kleptomania". The goal of the proposed study is to evaluate the efficacy and safety of naltrexone in kleptomania.
What is the current status of trial NCT00332579?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2006-05-01. Estimated completion is 2008-09-01.
What conditions does trial NCT00332579 study?
This clinical trial studies the following conditions: Kleptomania.
What interventions are being tested in trial NCT00332579?
The interventions under investigation include: Placebo (DRUG), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT00332579?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00332579 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00332579's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI